CN114262343B - 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, and preparation method and application thereof - Google Patents
2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, and preparation method and application thereof Download PDFInfo
- Publication number
- CN114262343B CN114262343B CN202111553467.5A CN202111553467A CN114262343B CN 114262343 B CN114262343 B CN 114262343B CN 202111553467 A CN202111553467 A CN 202111553467A CN 114262343 B CN114262343 B CN 114262343B
- Authority
- CN
- China
- Prior art keywords
- methyl
- propyltin
- phenyl
- tris
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZUCRGHABDDWQPY-UHFFFAOYSA-N pyrazine-2,3-dicarboxylic acid Chemical compound OC(=O)C1=NC=CN=C1C(O)=O ZUCRGHABDDWQPY-UHFFFAOYSA-N 0.000 title claims abstract description 68
- FBIVKLDWLAMJMB-UHFFFAOYSA-N propyltin Chemical compound CCC[Sn] FBIVKLDWLAMJMB-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000010668 complexation reaction Methods 0.000 title description 2
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 16
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 16
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 10
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 10
- 201000007270 liver cancer Diseases 0.000 claims abstract description 10
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 10
- 239000007983 Tris buffer Substances 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 239000013078 crystal Substances 0.000 claims description 18
- -1 polytetrafluoroethylene Polymers 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 16
- HOXINJBQVZWYGZ-UHFFFAOYSA-N fenbutatin oxide Chemical compound C=1C=CC=CC=1C(C)(C)C[Sn](O[Sn](CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C1=CC=CC=C1 HOXINJBQVZWYGZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000003560 cancer drug Substances 0.000 claims description 10
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 10
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 abstract description 9
- 201000005249 lung adenocarcinoma Diseases 0.000 abstract description 9
- 230000001093 anti-cancer Effects 0.000 abstract description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 229910052697 platinum Inorganic materials 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 22
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002390 rotary evaporation Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000012258 culturing Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008204 material by function Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910001887 tin oxide Inorganic materials 0.000 description 2
- FIDXVVHZWRFINX-UHFFFAOYSA-N tris(2-methyl-2-phenylpropyl)tin Chemical compound C=1C=CC=CC=1C(C)(C)C[Sn](CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C1=CC=CC=C1 FIDXVVHZWRFINX-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, the structure of which is shown as a formula I. The invention also provides a preparation method of the 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex and application thereof in preparing anticancer drugs. The 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex of the invention has good anticancer activity on human cervical cancer cells, human liver cancer cells, human lung adenocarcinoma cells, human breast cancer cells and the like. Compared with the currently commonly used platinum anti-cancer drugs, the 2, 3-pyrazine diacid bis [ tri (2-methyl-2-phenyl) propyltin ] complex has higher anti-cancer activity, and the preparation method is simple and quick, has lower preparation cost, can be suitable for industrialized mass production, and provides a new way for developing anti-cancer drugs.
Description
Technical Field
The invention belongs to the technical field of chemical synthesis, and particularly relates to a 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, a preparation method and application thereof.
Background
Organotin carboxylates are receiving extensive attention from researchers due to their biological activity. However, the known organotin compounds are generally highly toxic and therefore limited in application. Therefore, optimizing the structure of the organotin complex through design, thereby regulating the balance between toxicity and biological activity of the organotin complex is an important direction of research at present. In general, the toxicity of an organotin compound is related to its relative molecular mass, with smaller relative molecular mass being more toxic and larger relative molecular mass being more bulky alkyl tin. Therefore, the novel large steric hindrance alkyl tin complex is synthesized, and the structure and the biological activity of the complex are researched, so that the complex has important research significance.
Nitrogen heterocycles are important and common structural units for medicines, pesticides, functional materials, etc., most of which are closely related to living systems. Based on the fact that bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide is a substance with better biological activity, and the 2-methyl-2-phenylpropyl has the characteristics of larger steric hindrance, larger molecular weight and the like, the disclosed research is not reported much at present.
Disclosure of Invention
In order to solve the defects existing in the prior art, the primary aim of the invention is to provide a 2, 3-pyrazine diacid bis [ tri (2-methyl-2-phenyl) propyl tin ] complex.
It is another object of the present invention to provide a method for preparing the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex.
It is a further object of the present invention to provide the use of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex.
The aim of the invention is achieved by the following technical scheme:
a2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex has the structure shown in formula I:
further, the melting point of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex is 122-124 ℃.
Further, the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin]The molecular formula of the complex is C 66 H 80 N 2 O 4 Sn 2 。
Further, the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin]The crystal of the complex is monoclinic crystal, and the space group P2 1 The crystallographic parameters were as follows: a= 1.14618 (5) nm, b= 1.88650 (8) nm, c= 2.92848 (12) nm, α=γ=90°, β= 94.402 (10) °, z=2, v= 6.3135 (5) nm 3 ，D c ＝1.265g/cm 3 ，μ(MoKa)＝8.36cm -1 ，F(000)＝2488，R 1 ＝0.0378，wR 2 ＝0.0828。
Further, the preparation method of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
sequentially adding methanol, bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 2, 3-pyrazinedicarboxylic acid into a polytetrafluoroethylene microwave reaction tank, sealing a tank cover, placing the tank cover in a microwave reactor, performing microwave radiation reaction at 115-125 ℃ for 1.5-2.5 hours, rotationally evaporating to remove part of solvent, standing until white solid is separated out, and recrystallizing the white solid with benzene to obtain colorless crystal bis [ tris (2-methyl-2-phenyl) propyltin ] 2, 3-pyrazinedicarboxylic acid complex; the molar ratio of the bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide to the 2, 3-pyrazinedicarboxylic acid is 1:1; 35-45mL of methanol is added per millimole of 2, 3-pyrazinedioic acid.
Further, the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex is used for preparing anticancer drugs.
Further, the anticancer drug comprises cervical cancer resistant drug, liver cancer resistant drug, lung adenocarcinoma resistant drug or breast cancer resistant drug.
Compared with the prior art, the invention has the following advantages and effects:
the 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex disclosed by the invention has good anticancer activity on human cervical cancer cells, human liver cancer cells, human lung adenocarcinoma cells, human breast cancer cells and the like, and can be used for preparing anticancer drugs such as anti-cervical cancer drugs, anti-liver cancer drugs, anti-lung adenocarcinoma drugs or anti-breast cancer drugs. Compared with the currently commonly used platinum anti-cancer drugs, the 2, 3-pyrazine diacid bis [ tri (2-methyl-2-phenyl) propyltin ] complex has higher anti-cancer activity, and the preparation method is simple and quick, has lower preparation cost, can be suitable for industrialized mass production, and provides a new way for developing anti-cancer drugs.
Drawings
FIG. 1Bis [ tris (2-methyl-2-phenyl) propyltin ] 2, 3-pyrazinedicarboxylate according to the present invention]Complexes of 1 HNMR spectrogram;
FIG. 2 is a diagram of bis [ tris (2-methyl-2-phenyl) propyltin 2, 3-pyrazinedicarboxylate according to the present invention]Complexes of 13 CNMR spectrogram;
FIG. 3 is a molecular crystal structure diagram of the bis [ tris (2-methyl-2-phenyl) propyltin ] 2, 3-pyrazinedicarboxylate complex of the present invention.
Detailed Description
The present invention will be described in further detail with reference to examples, but embodiments of the present invention are not limited thereto.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, the term "comprising" or "including" can be open, semi-closed, and closed. In other words, the term also includes "consisting essentially of …," or "consisting of ….
The known organotin compounds are generally highly toxic and therefore limited in application. In general, the toxicity of an organotin compound is related to its relative molecular mass, with smaller relative molecular mass being more toxic and larger relative molecular mass being more bulky alkyl tin. Therefore, the novel large steric hindrance alkyl tin complex is synthesized, and the structure and the biological activity of the complex are researched, so that the complex has important research significance. Nitrogen heterocycles are important and common structural units for medicines, pesticides, functional materials, etc., most of which are closely related to living systems. Based on the fact that bis [ tris (2-methyl-2-phenylpropyl) ] tin oxide is a substance with better biological activity, and the 2-methyl-2-phenylpropyl has the characteristics of larger steric hindrance, larger molecular weight and the like, the disclosed research is not reported much at present.
Specifically, the embodiment of the invention provides a 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex, the structure of which is shown in a formula I:
further, the melting point of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex is 122-124 ℃.
Further, the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin]The molecular formula of the complex is C 66 H 80 N 2 O 4 Sn 2 . Wherein: calculated value (%): c,65.85; h,6.65; n,2.28. Measured value (%): c,65.52; h,6.78; n,2.32.
Further, as shown in fig. 1 to 2, the spectral data are as follows:
IR(KBr，cm -1 )：3084.18，3057.17，2962.86，2922.16，1680.00，1664.57，1598.99，1494.83，1442.75，1382.96，1323.17，555.50，4453.27。
NMR： 1 H NMR(CDCl 3 ,500MHz)δ8.62(s,2H),7.30-7.27(m,12H),7.22-7.19(m,6H),7.08-7.06(m,12H),1.35(s,12H),1.25(s,36H)；
13 C NMR(CDCl 3 ,125MHz)δ168.84,151.06,147.65,143.87,128.42,125.82,125.38,37.75,37.61,32.95； 119 Sn NMR(CDCl 3 ,187MHz,Me 4 Sn)δ110.47。
further, as shown in FIG. 3, the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin]The crystal of the complex is monoclinic crystal, and the space group P2 1 The crystallographic parameters were as follows: a= 1.14618 (5) nm, b= 1.88650 (8) nm, c= 2.92848 (12) nm, α=γ=90°, β= 94.402 (10) °, z=2, v= 6.3135 (5) nm 3 ，D c ＝1.265g/cm 3 ，μ(MoKa)＝8.36cm -1 ，F(000)＝2488，R 1 ＝0.0378，wR 2 ＝0.0828。
Further, the preparation method of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
sequentially adding methanol, bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 2, 3-pyrazinedicarboxylic acid into a polytetrafluoroethylene microwave reaction tank, sealing a tank cover, placing the tank cover in a microwave reactor, performing microwave radiation reaction at 115-125 ℃ for 1.5-2.5 hours, rotationally evaporating to remove part of solvent, standing until white solid is separated out, and recrystallizing the white solid with benzene to obtain colorless crystal bis [ tris (2-methyl-2-phenyl) propyltin ] 2, 3-pyrazinedicarboxylic acid complex; the molar ratio of the bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide to the 2, 3-pyrazinedicarboxylic acid is 1:1; 35-45mL of methanol is added per millimole of 2, 3-pyrazinedioic acid.
Further, the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex is used for preparing anticancer drugs.
Further, the anticancer drug comprises cervical cancer resistant drug, liver cancer resistant drug, lung adenocarcinoma resistant drug or breast cancer resistant drug.
Example 1
A preparation method of 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
35mL of methanol, 1.052g (1 mmol) of bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 0.168g (1 mmol) of 2, 3-pyrazinedioic acid were sequentially added into a polytetrafluoroethylene microwave reaction tank, the tank cover was sealed, the tank cover was placed in a microwave reactor, a microwave radiation reaction was carried out at 120 ℃ for 2 hours, a part of the solvent was removed by rotary evaporation, the tank cover was allowed to stand until a white solid was precipitated, and the white solid was recrystallized from benzene to obtain colorless crystals of 0.908g of bis [ tris (2-methyl-2-phenyl) propyltin ] 2, and the yield was 75.45%.
Example 2
A preparation method of 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
40mL of methanol, 1.1572g (1.1 mmol) of bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 0.1848g (1.1 mmol) of 2, 3-pyrazinedioic acid are sequentially added into a polytetrafluoroethylene microwave reaction tank, the tank cover is sealed, the tank cover is placed in a microwave reactor, microwave radiation reaction is carried out at 120 ℃ for 2.0h, partial solvent is removed by rotary evaporation, the tank cover is stood until white solid is separated out, benzene is used for recrystallising the white solid, and 0.940g of colorless crystal of the bis [ tris (2-methyl-2-phenyl) propyltin ] 2, 3-pyrazinedioic acid complex is obtained, and the yield is 78.10%.
Example 3
A preparation method of 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
45mL of methanol, 1.1046g (1.05 mmol) of bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 0.1764g (1.05 mmol) of 2, 3-pyrazinedioic acid are sequentially added into a polytetrafluoroethylene microwave reaction tank, the tank cover is sealed, the tank cover is placed in a microwave reactor, microwave radiation reaction is carried out at 120 ℃ for 2.0h, partial solvent is removed by rotary evaporation, the tank cover is placed until white solid is separated out, benzene is used for recrystallization, and colorless crystals of 0.941g of the bis [ tris (2-methyl-2-phenyl) propyltin ] complex of 2, 3-pyrazinedioic acid are obtained, and the yield is 78.23%.
Example 4
A preparation method of 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
40mL of methanol, 1.1046g (1.05 mmol) of bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 0.1764g (1.05 mmol) of 2, 3-pyrazinedioic acid are sequentially added into a polytetrafluoroethylene microwave reaction tank, the tank cover is sealed, the tank cover is placed in a microwave reactor, the microwave radiation reaction is carried out for 2.0h at 115 ℃, part of the solvent is removed by rotary evaporation, the tank cover is placed until white solid is separated out, benzene is used for recrystallization, colorless crystals of 0.861g of the bis [ tris (2-methyl-2-phenyl) propyltin ] complex of 2, 3-pyrazinedioic acid are obtained, and the yield is 72.14%.
Example 5
A preparation method of 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
40mL of methanol, 1.1046g (1.05 mmol) of bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 0.1764g (1.05 mmol) of 2, 3-pyrazinedioic acid are sequentially added into a polytetrafluoroethylene microwave reaction tank, the tank cover is sealed, the tank cover is placed in a microwave reactor, microwave radiation reaction is carried out for 2.0h at 125 ℃, part of the solvent is removed by rotary evaporation, the tank cover is placed until white solid is separated out, benzene is used for recrystallization, and colorless crystals of 0.922g of the bis [ tris (2-methyl-2-phenyl) propyltin ] complex of 2, 3-pyrazinedioic acid are obtained, and the yield is 76.58%.
Example 6
A preparation method of 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
40mL of methanol, 1.1046g (1.05 mmol) of bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 0.1764g (1.05 mmol) of 2, 3-pyrazinedioic acid are sequentially added into a polytetrafluoroethylene microwave reaction tank, the tank cover is sealed, the tank cover is placed in a microwave reactor, microwave radiation reaction is carried out at 120 ℃ for 1.5h, partial solvent is removed by rotary evaporation, the tank cover is placed until white solid is separated out, benzene is used for recrystallization, and colorless crystals of 0.872g of the bis [ tris (2-methyl-2-phenyl) propyltin ] complex of 2, 3-pyrazinedioic acid are obtained, and the yield is 72.43%.
Example 7
A preparation method of 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex comprises the following steps:
40mL of methanol, 1.1046g (1.05 mmol) of bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 0.1764g (1.05 mmol) of 2, 3-pyrazinedioic acid are sequentially added into a polytetrafluoroethylene microwave reaction tank, the tank cover is sealed, the tank cover is placed in a microwave reactor, microwave radiation reaction is carried out at 120 ℃ for 2.5h, partial solvent is removed by rotary evaporation, the tank cover is placed until white solid is separated out, benzene is used for recrystallizing the white solid, and colorless crystals of 0.943g of bis [ tris (2-methyl-2-phenyl) propyltin ] complex of 2, 3-pyrazinedioic acid are obtained, and the yield is 78.38%.
Effect examples
Antitumor activity was tested on the basis of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex prepared in example 1.
The in vitro growth inhibition activity of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex on tumor cells, human cervical cancer cells (Hela), human liver cancer cells (HuH-7), human non-small cell lung cancer cells (a 549), human lung adenocarcinoma cells (H1975), breast cancer (MCF-7) and normal cells, human kidney epithelial cells (293T), was examined by the MTT method.
The compound was formulated with dimethyl sulfoxide (DMSO) at 5.0mg/mLIs diluted to 5,10,25,50,100. Mu.g/mL with RPMI-1640 medium, respectively. HeLa cell suspension in exponential growth phase was added to 96-well plates (cell concentration: 50000/mL, 100. Mu.L/well) at 37℃with 5% CO 2 Culturing in an incubator for 12-18h to adhere cells. Removing the supernatant, adding 100 mu L of the compound with different concentrations, setting 4 compound holes at each concentration, incubating for 24 hours, discarding the supernatant, adding 60 mu L of MTT solution with concentration of 2.0mg/mL into each hole, continuously culturing for 3 hours, adding 150 mu L of dimethyl sulfoxide into each hole after removing the supernatant, oscillating for 10 minutes at a low speed to dissolve the deep blue crystal, and measuring the absorbance value at 490nm by using an enzyme-labeled instrument. The inhibition rate of each group on cancer cells was calculated as follows: inhibition (%) = (control OD value-test OD value)/control OD value x 100%. Each set of experiments was repeated 3 times and the average was taken. The half Inhibitory Concentration (IC) of the sample on the cells was calculated by linear regression of the log concentration and the cell inhibition ratio using the spss17.0 software 50 Values), activity data are shown in table 1. As can be seen from Table 1, the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] prepared according to the present invention]The complex has good anticancer activity on human cervical cancer cells, human liver cancer cells, human lung adenocarcinoma cells, human breast cancer cells and the like.
TABLE 1 in vitro Activity test data for 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] Complex anticancer drugs
From table 1, it can be seen that the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex of the present invention shows good anticancer activity against human cervical cancer cells, human liver cancer cells, human lung adenocarcinoma cells, human breast cancer cells, etc., and can be used for preparing anticancer drugs such as anti-cervical cancer drugs, anti-liver cancer drugs, anti-lung adenocarcinoma drugs, or anti-breast cancer drugs. Compared with the currently commonly used platinum anti-cancer drugs, the 2, 3-pyrazine diacid bis [ tri (2-methyl-2-phenyl) propyltin ] complex has higher anti-cancer activity, and the preparation method is simple and quick, has lower preparation cost, can be suitable for industrialized mass production, and provides a new way for developing anti-cancer drugs.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (6)
1. The 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex is characterized in that the structure is shown as formula one:
the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin]The crystal of the complex is monoclinic crystal, and the space group P2 1 The crystallographic parameters were as follows: a= 1.14618 (5) nm, b= 1.88650 (8) nm, c= 2.92848 (12) nm, α=γ=90°, β= 94.402 (10) °, z=2, v= 6.3135 (5) nm 3 ，D c ＝1.265g/cm 3 ，μ(MoKa)＝8.36cm -1 ，F(000)＝2488，R 1 ＝0.0378，wR 2 ＝0.0828。
2.2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex according to claim 1, characterized in that the melting point of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex is 122-124 ℃.
3. 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] according to claim 1]A complex characterized in that the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin]The molecular formula of the complex is C 66 H 80 N 2 O 4 Sn 2 。
4. A process for the preparation of the bis [ tris (2-methyl-2-phenyl) propyltin ] 2, 3-pyrazinedicarboxylate according to any one of claims 1 to 3, comprising the steps of:
sequentially adding methanol, bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide and 2, 3-pyrazinedicarboxylic acid into a polytetrafluoroethylene microwave reaction tank, sealing a tank cover, placing the tank cover in a microwave reactor, performing microwave radiation reaction at 115-125 ℃ for 1.5-2.5 hours, rotationally evaporating to remove part of solvent, standing until white solid is separated out, and recrystallizing the white solid with benzene to obtain colorless crystal bis [ tris (2-methyl-2-phenyl) propyltin ] 2, 3-pyrazinedicarboxylic acid complex; the molar ratio of the bis [ tris (2-methyl-2-phenylpropyl) tin ] oxide to the 2, 3-pyrazinedicarboxylic acid is 1:1; 35-45mL of methanol is added per millimole of 2, 3-pyrazinedioic acid.
5. Use of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex according to any one of claims 1 to 3 for the preparation of anticancer drugs.
6. The use of the 2, 3-pyrazinedicarboxylic acid bis [ tris (2-methyl-2-phenyl) propyltin ] complex according to claim 5, wherein the anticancer drug includes an anti-cervical cancer drug, an anti-liver cancer drug, an anti-lung cancer drug, or an anti-breast cancer drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111553467.5A CN114262343B (en) | 2021-12-17 | 2021-12-17 | 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111553467.5A CN114262343B (en) | 2021-12-17 | 2021-12-17 | 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114262343A CN114262343A (en) | 2022-04-01 |
| CN114262343B true CN114262343B (en) | 2024-03-22 |
Family
ID=80827791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111553467.5A Active CN114262343B (en) | 2021-12-17 | 2021-12-17 | 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114262343B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583157A (en) * | 1994-04-12 | 1996-12-10 | Pharmachemie B.V. | Dibutyltin bis(dihydroxybenzoates) and compositions containing these compounds |
| CN106279256A (en) * | 2016-08-16 | 2017-01-04 | 衡阳师范学院 | A kind of double [three (2 methyl 2 phenyl) propyl group stannum] 2,2 ' biphenyl dicarboxylic acid ester coordination compounds and preparation method and application |
| CN110128466A (en) * | 2019-05-31 | 2019-08-16 | 衡阳师范学院 | Three (2- methyl -2- phenyl) propyl tin 3- indolebutyric acid ester complexs of one kind and preparation method and application |
| CN111057092A (en) * | 2019-12-26 | 2020-04-24 | 衡阳师范学院 | Tris (2-methyl-2-phenylpropyl) tin 3-aminopiperazine acid ester complex, preparation method and application thereof |
| CN111057097A (en) * | 2019-12-26 | 2020-04-24 | 衡阳师范学院 | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyl tin ] 3-nitroisophthalate |
| CN111138488A (en) * | 2019-12-26 | 2020-05-12 | 衡阳师范学院 | Preparation method and application of bis [ tri (2-methyl-2-phenylpropyl) ] tin isophthalate complex |
| CN111138484A (en) * | 2019-12-26 | 2020-05-12 | 衡阳师范学院 | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyl tin ] fumarate complex |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111333676A (en) * | 2020-04-18 | 2020-06-26 | 台州泰捷化工科技有限公司 | Alkyl tin complex with antitumor activity and preparation method thereof |
-
2021
- 2021-12-17 CN CN202111553467.5A patent/CN114262343B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583157A (en) * | 1994-04-12 | 1996-12-10 | Pharmachemie B.V. | Dibutyltin bis(dihydroxybenzoates) and compositions containing these compounds |
| CN106279256A (en) * | 2016-08-16 | 2017-01-04 | 衡阳师范学院 | A kind of double [three (2 methyl 2 phenyl) propyl group stannum] 2,2 ' biphenyl dicarboxylic acid ester coordination compounds and preparation method and application |
| CN110128466A (en) * | 2019-05-31 | 2019-08-16 | 衡阳师范学院 | Three (2- methyl -2- phenyl) propyl tin 3- indolebutyric acid ester complexs of one kind and preparation method and application |
| CN111057092A (en) * | 2019-12-26 | 2020-04-24 | 衡阳师范学院 | Tris (2-methyl-2-phenylpropyl) tin 3-aminopiperazine acid ester complex, preparation method and application thereof |
| CN111057097A (en) * | 2019-12-26 | 2020-04-24 | 衡阳师范学院 | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyl tin ] 3-nitroisophthalate |
| CN111138488A (en) * | 2019-12-26 | 2020-05-12 | 衡阳师范学院 | Preparation method and application of bis [ tri (2-methyl-2-phenylpropyl) ] tin isophthalate complex |
| CN111138484A (en) * | 2019-12-26 | 2020-05-12 | 衡阳师范学院 | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyl tin ] fumarate complex |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114262343A (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110713500B (en) | Palladium complex using 2-benzoylpyridine thiosemicarbazone and synthetic method thereof | |
| CN110950914B (en) | Iridium complex and synthesis method and application thereof | |
| CN108774269B (en) | Novel targeted benzimidazole derivative antitumor platinum (II) and ruthenium (II) complex and preparation method and application thereof | |
| Da et al. | Synthesis, structure and properties of two series of platinum (II) complexes containing methyleugenol or chelating methyleugenol and amine | |
| CN110330534B (en) | Novel 2-phenylpyridine-platinum (IV) precursor anticancer complex and synthesis method and application thereof | |
| CN111205311A (en) | Novel high-antitumor-activity white leaf vine zinc (II) complex and synthesis method and application thereof | |
| CN111253418A (en) | Novel white leaf vine zinc (II) complex and synthesis method and application thereof | |
| CN108558952B (en) | 2-phenylpyridine binuclear palladium (II) complex and preparation method and application thereof | |
| CN114262343B (en) | 2, 3-pyrazinedicarboxylic acid bis [ tri (2-methyl-2-phenyl) propyltin ] complex, and preparation method and application thereof | |
| CN114805404B (en) | Metal complex based on dehydroabietylamine and preparation method and application thereof | |
| CN111138372A (en) | Preparation and application of acetylpyrazine thiosemicarbazone metal chelating agent and metal complex thereof | |
| CN107827934B (en) | Tetravalent platinum complex with anticancer activity, preparation method and application | |
| Fernandes et al. | Studies on polymorph conversion in a new cyclodextrin inclusion compound | |
| CN110172075B (en) | Novel coumarin-quinoline-platinum (II) complex and synthesis method and application thereof | |
| Carmona et al. | Formation of zwitterionic ligands, ROC-(+ PMe3) S2-, by nucleophilic attack of trimethylphosphine on coordinated xanthates. X-ray structure of MoO [S2C (PMe3) O-iso-Pr-S, S'](CS2CO-iso-Pr-S, S'C) | |
| CN109824572B (en) | Structure, preparation and application of 4-hydroxybenzophenone hydrazone-1-methyl-3 indole formaldehyde Schiff base | |
| CN110105402B (en) | Berberine antitumor platinum (II) complex and synthesis method and application thereof | |
| CN110698383B (en) | Structure, synthesis and application of benzil hydrazone-3-acetyl indole | |
| CN111333676A (en) | Alkyl tin complex with antitumor activity and preparation method thereof | |
| Liu et al. | Synthesis and cancer cell cytotoxicity of gold (III) tetraarylporphyrins with a C5-carboxylate substituent | |
| CN111138474B (en) | Tricyclohexyltin 2-bromothiophene-5-formate complex and preparation method and application thereof | |
| CN110156842B (en) | Coumarin-platinum (II) complex targeting lung cancer drug-resistant strain and synthesis method and application thereof | |
| CN108623638B (en) | 12-chlorobenzimidazole-1, 8-naphthalimide-platinum complex and preparation method and application thereof | |
| CN109021021B (en) | 11, 12-dichlorobenzimidazole-1, 8-naphthalimide-platinum complex and preparation method and application thereof | |
| CN111848498B (en) | Piperidine and 2, 6-piperiddione colchicine site inhibitor and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |